SCHEMBL4180201

SCHEMBL4180201

O=C(c1csc(NS(=O)(=O)c2ccccc2)n1)N1CCCC1c1ccccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 5/20 0.49
TRPC3 Q13507 3/20 0.48
TRPC6 Q9Y210 3/20 0.48
SCD5 Q86SK9 1/20 0.45
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
ADAM17 P78536 1/20 0.41
TRPA1 O75762 1/20 0.40
CACNA1C Q13936 1/20 0.40
SCN5A Q14524 1/20 0.40
TRPV1 Q8NER1 1/20 0.40
TRPV4 Q9HBA0 1/20 0.40
KDM1A O60341 1/20 0.40
CPT1A P50416 2/20 0.40
KCNK3 O14649 1/20 0.40
CPT2 P23786 1/20 0.40
HSD11B1 P28845 1/20 0.40
SCD O00767 1/20 0.39
MEN1 O00255 1/20 0.39
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4172975 0.97 TRPC3 (0.51) SCN9ATRPC3TRPC6SCD5NPC1
SCHEMBL4177283 0.97 TRPC3 (0.51) SCN9ATRPC3TRPC6SCD5NPC1
SCHEMBL4169816 0.96 TRPC3 (0.51) SCN9ATRPC3TRPC6SCD5NPC1
SCHEMBL4172925 0.88 TRPC3 (0.49) SCN9ATRPC3TRPC6SCD5TRPA1
SCHEMBL4172599 0.88 TRPC3 (0.61) SCN9ATRPC3TRPC6SCD5TRPA1
SCHEMBL4165105 0.85 TRPC3 (0.66) SCN9ATRPC3TRPC6SCD5SCD
SCHEMBL4170692 0.84 TRPC3 (0.65) SCN9ATRPC3TRPC6SCD5SCD
SCHEMBL4179996 0.83 SCN9A (0.51) SCN9ATRPC3TRPC6SCD5TRPA1
SCHEMBL4177686 0.83 SCN9A (0.51) SCN9ATRPC3TRPC6NPC1RAB9A
SCHEMBL4176159 0.81 TRPC3 (0.61) SCN9ATRPC3TRPC6SCD5TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN9A 51/4885TRPC3 57/4885TRPC6 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.